NCT03981796: An ongoing trial by Tesaro, Inc.
This trial is ongoing. It must report results 1 year, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03981796 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 18, 2019 |
| Completion date | Nov. 26, 2026 |
| Required reporting date | Nov. 26, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 22, 2026 |
| Days late | None |